Your browser doesn't support javascript.
loading
Transcriptional, epigenetic and metabolic signatures in cardiometabolic syndrome defined by extreme phenotypes.
Seyres, Denis; Cabassi, Alessandra; Lambourne, John J; Burden, Frances; Farrow, Samantha; McKinney, Harriet; Batista, Joana; Kempster, Carly; Pietzner, Maik; Slingsby, Oliver; Cao, Thong Huy; Quinn, Paulene A; Stefanucci, Luca; Sims, Matthew C; Rehnstrom, Karola; Adams, Claire L; Frary, Amy; Ergüener, Bekir; Kreuzhuber, Roman; Mocciaro, Gabriele; D'Amore, Simona; Koulman, Albert; Grassi, Luigi; Griffin, Julian L; Ng, Leong Loke; Park, Adrian; Savage, David B; Langenberg, Claudia; Bock, Christoph; Downes, Kate; Wareham, Nicholas J; Allison, Michael; Vacca, Michele; Kirk, Paul D W; Frontini, Mattia.
Afiliación
  • Seyres D; National Institute for Health Research BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, UK. ds777@medschl.cam.ac.uk.
  • Cabassi A; Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK. ds777@medschl.cam.ac.uk.
  • Lambourne JJ; NHS Blood and Transplant, Cambridge Biomedical Campus, Cambridge, UK. ds777@medschl.cam.ac.uk.
  • Burden F; MRC Biostatistics Unit, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.
  • Farrow S; National Institute for Health Research BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, UK.
  • McKinney H; Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.
  • Batista J; NHS Blood and Transplant, Cambridge Biomedical Campus, Cambridge, UK.
  • Kempster C; National Institute for Health Research BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, UK.
  • Pietzner M; Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.
  • Slingsby O; NHS Blood and Transplant, Cambridge Biomedical Campus, Cambridge, UK.
  • Cao TH; National Institute for Health Research BioResource, Cambridge University Hospitals, Cambridge Biomedical Campus, Cambridge, UK.
  • Quinn PA; Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.
  • Stefanucci L; NHS Blood and Transplant, Cambridge Biomedical Campus, Cambridge, UK.
  • Sims MC; Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.
  • Rehnstrom K; Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.
  • Adams CL; Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.
  • Frary A; MRC Epidemiology Unit, University of Cambridge, Cambridge, UK.
  • Ergüener B; Department of Cardiovascular Sciences, Glenfield Hospital, University of Leicester, Leicester, UK.
  • Kreuzhuber R; National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK.
  • Mocciaro G; Department of Cardiovascular Sciences, Glenfield Hospital, University of Leicester, Leicester, UK.
  • D'Amore S; National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK.
  • Koulman A; Department of Cardiovascular Sciences, Glenfield Hospital, University of Leicester, Leicester, UK.
  • Grassi L; National Institute for Health Research Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK.
  • Griffin JL; Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.
  • Ng LL; NHS Blood and Transplant, Cambridge Biomedical Campus, Cambridge, UK.
  • Park A; British Heart Foundation Centre of Excellence, Cambridge Biomedical Campus, Cambridge, UK.
  • Savage DB; Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.
  • Langenberg C; NHS Blood and Transplant, Cambridge Biomedical Campus, Cambridge, UK.
  • Bock C; Oxford Haemophilia and Thrombosis Centre, Oxford University Hospitals NHS Foundation Trust, NIHR Oxford Biomedical Research Centre, Oxford, UK.
  • Downes K; Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.
  • Wareham NJ; Metabolic Research Laboratories, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, CB2 0QQ, UK.
  • Allison M; Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.
  • Vacca M; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
  • Kirk PDW; Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.
  • Frontini M; European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, UK.
Clin Epigenetics ; 14(1): 39, 2022 03 12.
Article en En | MEDLINE | ID: mdl-35279219
ABSTRACT

BACKGROUND:

This work is aimed at improving the understanding of cardiometabolic syndrome pathophysiology and its relationship with thrombosis by generating a multi-omic disease signature. METHODS/

RESULTS:

We combined classic plasma biochemistry and plasma biomarkers with the transcriptional and epigenetic characterisation of cell types involved in thrombosis, obtained from two extreme phenotype groups (morbidly obese and lipodystrophy) and lean individuals to identify the molecular mechanisms at play, highlighting patterns of abnormal activation in innate immune phagocytic cells. Our analyses showed that extreme phenotype groups could be distinguished from lean individuals, and from each other, across all data layers. The characterisation of the same obese group, 6 months after bariatric surgery, revealed the loss of the abnormal activation of innate immune cells previously observed. However, rather than reverting to the gene expression landscape of lean individuals, this occurred via the establishment of novel gene expression landscapes. NETosis and its control mechanisms emerge amongst the pathways that show an improvement after surgical intervention.

CONCLUSIONS:

We showed that the morbidly obese and lipodystrophy groups, despite some differences, shared a common cardiometabolic syndrome signature. We also showed that this could be used to discriminate, amongst the normal population, those individuals with a higher likelihood of presenting with the disease, even when not displaying the classic features.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Obesidad Mórbida / Síndrome Metabólico / Lipodistrofia Límite: Humans Idioma: En Revista: Clin Epigenetics Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Obesidad Mórbida / Síndrome Metabólico / Lipodistrofia Límite: Humans Idioma: En Revista: Clin Epigenetics Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido
...